A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This study is a Phase Ib/II, open-label, multicenter clinical trial. Here, the Study Phase Ib
is mainly to evaluate safety of Toripalimab + Cetuximab in treatment of relapsed or
metastatic HNSCC failing first-line platinum-based regimen and determine the recommended
Phase II dose (RP2D); the Study Phase II is mainly to evaluate efficacy and safety of the
combination in treatment of relapsed or metastatic HNSCC failing first-line platinum-based
regimen.